Methodology to calculate HPV Vaccine Coverage in the Region of the Americas

Abstract

This document focuses on monitoring HPV vaccine coverage data using administrative data. The introduction of the human papillomavirus (HPV) vaccine in the Expanded Program on Immunization (EPI) of the Americas started in 2006 (in the United States). As of June 2019, 40 countries and territories have this vaccine in their national vaccination schedules. The vaccine used most frequently is the quadrivalent (31/40), followed by the bivalent (7/40); and only two countries have used the nonavalent. Calculating and monitoring vaccination coverage is highly relevant in immunization programs to show achievements and problems, analyze their causes and take effective measures to attain expected results. This document focuses on the monitoring of HPV vaccine coverage data using administrative data. Countries may also conduct on-site follow-ups through rapid coverage monitoring or by taking more in-depth surveys; these two strategies are not covered herein... Objectives are: Establish a standard methodology to follow up on vaccine recipients and calculate HPV vaccine coverage in the Americas, allowing to: • Measure progress on vaccination of the target population selected by country, as well as define strategies to reach pertinent and equitable coverage. • Compare coverage levels obtained by different countries in the Region and from countries in other regions. • Compare regional coverage with that of other regions in the world.